Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector
The <i>feline immunodeficiency virus</i> (FIV) is a retrovirus with global impact and distribution, affecting both domestic and wild cats. This virus can cause severe and progressive immunosuppression culminating in the death of felids. Since the discovery of FIV, only one vaccine has be...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/10/1717 |
| _version_ | 1797469712213344256 |
|---|---|
| author | Luis A. F. Andrade Alice F. Versiani Edel F. Barbosa-Stancioli Jenner K. P. dos Reis Jordana Grazziela A. C. dos Reis Flavio G. da Fonseca |
| author_facet | Luis A. F. Andrade Alice F. Versiani Edel F. Barbosa-Stancioli Jenner K. P. dos Reis Jordana Grazziela A. C. dos Reis Flavio G. da Fonseca |
| author_sort | Luis A. F. Andrade |
| collection | DOAJ |
| description | The <i>feline immunodeficiency virus</i> (FIV) is a retrovirus with global impact and distribution, affecting both domestic and wild cats. This virus can cause severe and progressive immunosuppression culminating in the death of felids. Since the discovery of FIV, only one vaccine has been commercially available. This vaccine has proven efficiency against FIV subtypes A and D, whereas subtype B (FIV-B), found in multiple continents, is not currently preventable by vaccination. We, therefore, developed and evaluated a vaccine prototype against FIV-B using the recombinant viral vector modified vaccinia virus Ankara (MVA) expressing the variable region V1–V3 of the FIV-B envelope protein. We conducted preclinical tests in immunized mice (C57BL/6) using a prime-boost protocol with a 21 day interval and evaluated cellular and humoral responses as well the vaccine viability after lyophilization and storage. The animals immunized with the recombinant MVA/FIV virus developed specific splenocyte proliferation when stimulated with designed peptides. We also detected cellular and humoral immunity activation with IFN-y and antibody production. The data obtained in this study support further development of this immunogen and testing in cats. |
| first_indexed | 2024-03-09T19:24:09Z |
| format | Article |
| id | doaj.art-a60e24325e064df8b32141db4be9fd27 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T19:24:09Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-a60e24325e064df8b32141db4be9fd272023-11-24T03:04:49ZengMDPI AGVaccines2076-393X2022-10-011010171710.3390/vaccines10101717Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA VectorLuis A. F. Andrade0Alice F. Versiani1Edel F. Barbosa-Stancioli2Jenner K. P. dos Reis3Jordana Grazziela A. C. dos Reis4Flavio G. da Fonseca5Laboratory of Basic and Applied Virology, Federal University of Minas Gerais, Belo Horizonte 31270-901, BrazilDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555-0132, USALaboratory of Basic and Applied Virology, Federal University of Minas Gerais, Belo Horizonte 31270-901, BrazilRetroviruses Laboratory, Retrolab Federal University of Minas Gerais, Belo Horizonte 31270-901, BrazilLaboratory of Basic and Applied Virology, Federal University of Minas Gerais, Belo Horizonte 31270-901, BrazilLaboratory of Basic and Applied Virology, Federal University of Minas Gerais, Belo Horizonte 31270-901, BrazilThe <i>feline immunodeficiency virus</i> (FIV) is a retrovirus with global impact and distribution, affecting both domestic and wild cats. This virus can cause severe and progressive immunosuppression culminating in the death of felids. Since the discovery of FIV, only one vaccine has been commercially available. This vaccine has proven efficiency against FIV subtypes A and D, whereas subtype B (FIV-B), found in multiple continents, is not currently preventable by vaccination. We, therefore, developed and evaluated a vaccine prototype against FIV-B using the recombinant viral vector modified vaccinia virus Ankara (MVA) expressing the variable region V1–V3 of the FIV-B envelope protein. We conducted preclinical tests in immunized mice (C57BL/6) using a prime-boost protocol with a 21 day interval and evaluated cellular and humoral responses as well the vaccine viability after lyophilization and storage. The animals immunized with the recombinant MVA/FIV virus developed specific splenocyte proliferation when stimulated with designed peptides. We also detected cellular and humoral immunity activation with IFN-y and antibody production. The data obtained in this study support further development of this immunogen and testing in cats.https://www.mdpi.com/2076-393X/10/10/1717feline immunodeficiency virusmodified vaccinia virus Ankaravaccine |
| spellingShingle | Luis A. F. Andrade Alice F. Versiani Edel F. Barbosa-Stancioli Jenner K. P. dos Reis Jordana Grazziela A. C. dos Reis Flavio G. da Fonseca Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector Vaccines feline immunodeficiency virus modified vaccinia virus Ankara vaccine |
| title | Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector |
| title_full | Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector |
| title_fullStr | Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector |
| title_full_unstemmed | Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector |
| title_short | Developing a Feline Immunodeficiency Virus Subtype B Vaccine Prototype Using a Recombinant MVA Vector |
| title_sort | developing a feline immunodeficiency virus subtype b vaccine prototype using a recombinant mva vector |
| topic | feline immunodeficiency virus modified vaccinia virus Ankara vaccine |
| url | https://www.mdpi.com/2076-393X/10/10/1717 |
| work_keys_str_mv | AT luisafandrade developingafelineimmunodeficiencyvirussubtypebvaccineprototypeusingarecombinantmvavector AT alicefversiani developingafelineimmunodeficiencyvirussubtypebvaccineprototypeusingarecombinantmvavector AT edelfbarbosastancioli developingafelineimmunodeficiencyvirussubtypebvaccineprototypeusingarecombinantmvavector AT jennerkpdosreis developingafelineimmunodeficiencyvirussubtypebvaccineprototypeusingarecombinantmvavector AT jordanagrazzielaacdosreis developingafelineimmunodeficiencyvirussubtypebvaccineprototypeusingarecombinantmvavector AT flaviogdafonseca developingafelineimmunodeficiencyvirussubtypebvaccineprototypeusingarecombinantmvavector |